Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial

Fig. 4

The proportions of patients who tested positive for ADAs and, of those, the proportions who tested positive for NAbs, by study visit (safety population; TP3 and follow-up). aNAb-positive incidences are expressed as percentage of ADA-positive patients; not tested for ADAs. bn = 1. cn = 2; not tested for NAbs. dn = 1. ADA, anti-drug antibody; FU, follow-up; NAb, neutralizing antibody; TP3 treatment period 3

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us